Haemonetics Corporation reported a strong first quarter in fiscal year 2024, with a 19% increase in revenue to $311 million and adjusted earnings per diluted share of $1.05. The company's performance was driven by market-leading results across all business segments and advancements in innovation and commercial pipelines.
Revenue increased by 19% to $311 million.
Organic revenue increased by 21%.
Earnings per diluted share were $0.80.
Adjusted earnings per diluted share were $1.05.
The Company updated its previous fiscal 2024 GAAP total revenue and organic revenue growth guidance. Additionally, the Company reaffirmed its adjusted operating margin guidance and updated its adjusted earnings per diluted share guidance and free cash flow before restructuring and restructuring related costs guidance
Visualization of income flow from segment revenue to net income